Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 USD | +12.50% | +14.55% | +12.50% |
Business Summary
Number of employees: 100
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Immunotherapies
100.0
%
| 6 | 100.0 % | 8 | 100.0 % | +37.48% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 8 | 100.0 % | +37.48% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 69 | 19-06-30 | |
William Quinn
DFI | Director of Finance/CFO | 53 | 20-04-30 |
John Tomaro
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Edith Perez
CTO | Chief Tech/Sci/R&D Officer | 67 | 20-03-31 |
Priti Hegde
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Karen L. Bergman
IRC | Investor Relations Contact | - | - |
Sarah Nemec
PRN | Corporate Officer/Principal | - | 19-12-31 |
Yu Tai
LAW | General Counsel | - | - |
Wesley Burwell
HRO | Human Resources Officer | - | 20-12-31 |
Grant Yonehiro
PRN | Corporate Officer/Principal | 60 | 16-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Miller
BRD | Director/Board Member | 73 | 17-06-30 |
Mahendra Shah
BRD | Director/Board Member | 79 | 16-08-31 |
James Healy
BRD | Director/Board Member | 58 | 20-12-31 |
Kathy LaPorte
BRD | Director/Board Member | 62 | 20-11-30 |
Edgar Engleman
FOU | Founder | 78 | 15-01-21 |
Nicole Onetto
BRD | Director/Board Member | 71 | 21-12-13 |
Director/Board Member | 54 | 21-11-16 | |
Chief Executive Officer | 69 | 19-06-30 | |
Frank Lee
BRD | Director/Board Member | 56 | 21-11-16 |
Laura Berner
BRD | Director/Board Member | 49 | 22-12-13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,127,740 | 36,624,368 ( 96.06 %) | 0 | 96.06 % |
Company contact information
Bolt Biotherapeutics, Inc.
900 Chesapeake Drive
94063, Redwood City
+650 665 9295
http://www.boltbio.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.50% | 48.04M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- BOLT Stock
- Company Bolt Biotherapeutics, Inc.